Role of ecDNA in Cancer Progression

Cancer genomes are often described as unstable, rearranged, and highly adaptable. In many tumors, however, some of the most consequential genetic changes are not embedded within chromosomes at all. Instead, cancer-driving genomic regions can exist as circular DNA molecules outside the chromosomes. These structures are known as extrachromosomal DNA, or ecDNA.

ecDNA has gained increasing attention because it provides cancer cells with a flexible route to amplify oncogenes, alter transcriptional regulation, and generate intratumoral heterogeneity. Rather than following the stable inheritance patterns of chromosomal DNA, ecDNA can be unevenly distributed during cell division. This allows tumor cell populations to change rapidly, particularly under selective pressures such as therapy.

Large-scale genomic analyses have shown that ecDNA is not a rare curiosity. Bailey et al. reported ecDNA in 17.1% of tumor samples across 14,778 patients and 39 tumor types, with associations to tumor stage, metastasis, treatment exposure, and shorter overall survival. These findings position ecDNA as both a marker of aggressive tumor biology and a potential source of therapeutic vulnerability.

The therapeutic implications are especially relevant. ecDNA-positive cancers often carry highly amplified and highly transcribed oncogenes, which can create replication stress and transcription–replication conflicts. Recent work by Tang et al. suggests that this stress may be exploitable through CHK1 inhibition, opening the possibility of therapeutic strategies directed specifically at ecDNA-positive tumors.

What is ecDNA?

Extrachromosomal DNA describes circular DNA molecules that are located outside the normal chromosomal genome. In cancer, ecDNAs are often large, chromatinized, nuclear DNA structures that can contain complete genes as well as regulatory elements such as enhancers and promoters.

A defining feature of ecDNA is that it lacks a centromere. Centromeres are required for the accurate distribution of chromosomes during mitosis. Because ecDNA does not contain centromeres, it is not inherited with the same precision as chromosomal DNA. Instead, ecDNA molecules can segregate unevenly between daughter cells. One cell may inherit many copies of an oncogene-bearing circle, while another may receive fewer copies.

This irregular inheritance gives tumors a flexible genetic system outside the usual chromosomal framework. A chromosomal amplification is relatively fixed once established. An ecDNA amplification is more dynamic. Its copy number can vary between cells, it can cluster with other ecDNA molecules, and it can be selected for or against depending on the tumor environment.

How ecDNA Forms

ecDNA formation is closely linked to genomic instability. The process is not directed or intentional. Instead, chromosomal DNA can break, rearrange, and circularize during error-prone repair or catastrophic genomic events. If the resulting circular DNA contains genes or regulatory elements that provide a growth or survival advantage, cells carrying those ecDNAs may expand during tumor evolution.

Several mechanisms are thought to contribute to ecDNA formation. One important route is chromothripsis, a catastrophic event in which a chromosome or chromosomal region fragments and is then reassembled in an abnormal configuration. Some fragments may circularize and persist as ecDNA. Bailey et al. reported that complex ecDNA structures are consistent with catastrophic genomic processes such as chromothripsis.

Another proposed mechanism involves breakage–fusion–bridge cycles. These cycles can occur when chromosomes lose protective telomere function or undergo breakage. Repeated fusion and breakage events can generate focal amplifications and rearranged DNA fragments, some of which may contribute to extrachromosomal circular DNA formation.

DNA repair defects may also influence ecDNA biology. Tumors with impaired genome maintenance can accumulate rearrangements that increase the probability of circular DNA formation. Bailey et al. also linked ecDNA to mutational processes associated with environmental exposure and DNA repair deficiency, including tobacco-related signatures and homologous recombination repair deficiency.

More recent work by Sankar et al. adds another layer to ecDNA persistence. The authors identified retention elements, CpG-rich promoter-associated sequences that can tether episomal DNA to mitotic chromosomes. These elements increase the likelihood that circular DNA molecules are transmitted to daughter cells. This suggests that ecDNA structure is shaped not only by oncogene content, but also by features that help ecDNA persist across cell generations.

Suggested image placement: central “Circling in on cancer”-style figure.

The figure could show chromosomal DNA breakage, circularization, oncogene-bearing ecDNA formation, mitotic retention or unequal segregation, increased oncogene expression, tumor heterogeneity, and therapy resistance.

Genes Found on ecDNA

One of the major biological consequences of ecDNA is oncogene amplification. This should not be understood as a purposeful action by the cancer cell. Rather, genome instability can randomly generate circular DNA fragments, and those fragments may occasionally contain oncogenes or regulatory elements that increase cellular fitness. Tumor cells carrying advantageous ecDNA configurations can then be positively selected.

This distinction is important. ecDNA does not create cancer-driving genes from nothing. Instead, it can increase the copy number and regulatory activity of genes that already have oncogenic potential. When genes such as EGFR, ERBB2, FGFR1, FGFR2, PDGFRA, MYC, MDM2, CCND1, or CDK4 are present on ecDNA, their dosage and expression may increase substantially.

Bailey et al. reported that ecDNAs frequently carry oncogenes involved in major cancer pathways, including RTK–RAS signaling, TP53 regulation, and cell-cycle control. This includes genes such as EGFR, ERBB2, FGFR1, FGFR2, MDM2, CCND1, and CDK4.

ecDNA can also carry regulatory elements. Enhancers, promoters, and noncoding regulatory regions may be amplified together with oncogenes or may interact with oncogenes across different ecDNA molecules. This means ecDNA can act not only as a copy-number amplifier, but also as a platform for transcriptional rewiring.

Consequences for Cancer Cells

The cellular effects of ecDNA are broad. First, ecDNA can increase oncogene dosage. Multiple copies of an oncogene-bearing ecDNA molecule can lead to high levels of the encoded protein, strengthening growth and survival pathways.

Second, ecDNA can enhance transcriptional output. Because ecDNA can contain both genes and regulatory elements, it can bring oncogenes into contact with strong enhancers or promoter-associated regulatory regions. ecDNA molecules can also cluster in the nucleus, creating hubs of amplified transcriptional activity.

Third, ecDNA increases intratumoral heterogeneity. Because ecDNA segregates unevenly during mitosis, cells within the same tumor may differ in oncogene copy number and expression. This heterogeneity gives the tumor population more evolutionary flexibility. Under selective pressure, such as drug treatment, subclones with favorable ecDNA configurations may expand.

Fourth, ecDNA may influence immune interactions. Bailey et al. reported that ecDNAs can amplify immunomodulatory and inflammatory genes and that ecDNA carrying immunomodulatory genes was associated with reduced tumor T-cell infiltration. This connects ecDNA not only to genome instability and proliferative signaling, but also to mechanisms relevant to immune evasion.

Clinical Implications of ecDNA in Cancer

The presence of ecDNA has important clinical implications. Bailey et al. associated ecDNA detection with more advanced tumor stage, metastatic disease, prior treatment exposure, and shorter overall survival. This supports the view that ecDNA is a clinically relevant feature of aggressive cancer biology.

ecDNA may also contribute to therapy resistance. Because ecDNA copy number can vary dynamically between cells, tumors can rapidly shift their genetic composition under treatment pressure. Cells with ecDNA configurations that support survival may become enriched, leading to relapse or reduced therapeutic sensitivity.

This mechanism is especially relevant for tumors driven by amplified receptor tyrosine kinases or cell-cycle regulators. For example, ecDNA amplification of EGFR, ERBB2, FGFR2, PDGFRA, MDM2, or CDK4 may reinforce pathways that support proliferation, survival, and adaptation.

From a diagnostic perspective, ecDNA status may become useful for tumor stratification. Current approaches include whole-genome sequencing, computational reconstruction of focal amplifications, and cytogenetic methods such as fluorescence in situ hybridization. In selected tumor settings, probes against genes such as MDM2, CDK4, PDGFRA, and MYC may help visualize ecDNA-associated amplifications.

Therapeutic Implications

The same properties that make ecDNA biologically powerful may also create vulnerabilities. ecDNA-positive cells often carry highly amplified and highly transcribed oncogenes. This can create collisions between transcription and DNA replication, leading to replication stress and DNA damage.

Tang et al. showed that ecDNA-containing tumor cells display increased transcription–replication conflict and activation of the S-phase checkpoint kinase CHK1. Genetic or pharmacological CHK1 inhibition caused preferential death of ecDNA-containing tumor cells in experimental models.

In a gastric cancer model with FGFR2 amplified on ecDNA, the CHK1 inhibitor BBI-2779 suppressed tumor growth and prevented ecDNA-mediated acquired resistance to the FGFR inhibitor infigratinib. This suggests that ecDNA-directed therapeutic strategies may be especially valuable in combination with pathway-targeted therapies.

Another therapeutic concept is interference with ecDNA maintenance. Sankar et al. showed that retention elements can promote ecDNA transmission by tethering episomal DNA to mitotic chromosomes. In experimental systems, targeted cytosine methylation disrupted retention activity and contributed to ecDNA loss. Although this is not yet an established clinical strategy, it highlights ecDNA maintenance as a potential future therapeutic axis.

ecDNA-Associated Targets for Cancer Research

Because ecDNA frequently amplifies oncogenes and pathway regulators, proteins encoded by ecDNA-associated genes are important targets in cancer research. These targets are relevant for studying proliferative signaling, transcriptional activation, p53 pathway suppression, cell-cycle progression, and therapy resistance.

Pathway or biological process	Example targets	Relevance to ecDNA biology
RTK signaling	EGFR, ERBB2/HER2, FGFR1, FGFR2, PDGFRA	Amplification can enhance proliferative and survival signaling and may contribute to targeted therapy resistance.
MYC-driven transcription	MYC	Amplification can support broad transcriptional growth programs and metabolic rewiring.
TP53 pathway regulation	MDM2	Amplification can suppress p53-mediated tumor-suppressive responses.
Cell-cycle progression	CCND1, CDK4	Amplification can promote G1/S progression and uncontrolled proliferation.
DNA damage and replication stress response	CHK1, RPA2	ecDNA-positive cells may rely on checkpoint pathways to tolerate transcription–replication conflict and replication stress.

These targets provide useful entry points for studying ecDNA-associated tumor biology. Antibodies against RTK pathway members, MYC-associated signaling components, MDM2, CDK4, CCND1, CHK1, or replication stress markers may support research into ecDNA-driven proliferation, pathway activation, and therapeutic vulnerability.

References

1. Bailey C. et al. Origins and impact of extrachromosomal DNA. Nature. 2024;635:193–200. doi: 10.1038/s41586-024-08107-3. PMID: 39506150.
2. Sankar V. et al. Genetic elements promote retention of extrachromosomal DNA in cancer cells. Nature. 2026;649:152–160. doi: 10.1038/s41586-025-09764-8. PMID: 41261124.
3. Tang J. et al. Enhancing transcription–replication conflict targets ecDNA-positive cancers. Nature. 2024;635:211–220. doi: 10.1038/s41586-024-07802-5. PMID: 39506153.
4. Dong Y. et al. Extrachromosomal DNA (ecDNA) in cancer: mechanisms, clinical implications, and future perspectives. PMID: 37448518.
5. Hung K.L. et al. Coordinated inheritance of extrachromosomal DNAs in cancer cells. Nature. 2024. PMID: 39506152.